There are many different approaches to stable patients with atrial fibrillation who present to the emergency department. Personally, I have leaned towards electrical cardioversion over chemical cardioversion in patients in whom cardioversion is appropriate. In the places I work, it is usually faster and easier to get a patient sedated and electrically cardioverted than to […]
The post Vernakalant: shockingly fast without the shock? appeared first on First10EM.
Vernakalant is a medication primarily used for the rapid conversion of recent onset atrial fibrillation to normal sinus rhythm. Its mechanism of action involves blocking specific potassium channels and to a lesser extent, sodium channels within the atria, which helps to terminate the arrhythmia.
The drug is characterized by a rapid onset of action, typically inducing conversion within 10 to 15 minutes of intravenous administration, and has a relatively short half life. Clinical trials have shown Vernakalant to be effective, demonstrating significantly higher conversion rates to sinus rhythm compared to placebo, and often achieving conversion faster than other antiarrhythmic agents like amiodarone. For example, studies reported conversion rates for atrial fibrillation around 50 percent and higher for atrial flutter within 90 minutes.
From a safety perspective, common side effects can include taste disturbance, sneezing, and paresthesias. More serious, though less frequent, adverse events observed include hypotension and bradycardia. Crucially, Vernakalant has several contraindications. It should not be used in patients with severe heart failure, severe aortic stenosis, recent acute coronary syndromes within 30 days, or a prolonged QT interval at baseline. It is also not recommended for patients who have undergone surgery in the past three months, or those with severe bradycardia or sinus node dysfunction. The drug is given as an intravenous infusion.
https://first10em.com/vernakalant-shockingly-fast-without-the-shock/
